Phase 2 Immune System Diseases Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Lymphoproliferative DisordersImmune System DiseasesPeripheral T-cell Lymphomas
National Cancer Institute (NCI)330 enrolled2 locationsNCT03922724
Recruiting
Phase 2
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
Kidney DiseasesImmune System DiseasesAutoimmune Diseases+3 more
University of Leicester24 enrolled6 locationsNCT04663204
Recruiting
Phase 2
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
Immune System DiseasesPrimary Immune Regulatory DisorderAutoimmune Lymphoproliferative
Joseph Oved39 enrolled13 locationsNCT05787574
Recruiting
Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)354 enrolled2 locationsNCT02579967
Recruiting
Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Lymphoproliferative DisordersImmune System DiseasesCommon Variable Immunodeficiency+2 more
National Cancer Institute (NCI)66 enrolled1 locationNCT04339777
Recruiting
Phase 1Phase 2
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
Metabolic DiseaseDiabetes Mellitus, Type 1Type 1 Diabetes+14 more
Otsuka Pharmaceutical Factory, Inc.13 enrolled1 locationNCT06575426
Recruiting
Phase 1Phase 2
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D
Diabetes MellitusMetabolic DiseaseDiabetes Mellitus, Type 1+4 more
CRISPR Therapeutics AG40 enrolled2 locationsNCT05565248